Business Context and Reporting Period
This Form 8-K was filed by Oncobiologics, Inc. (noted as Outlook Therapeutics, Inc. in metadata) on April 26, 2018. The report addresses a regulatory notice regarding the company's stock listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on compliance with Nasdaq listing rules rather than financial performance metrics.
Material Changes
- Delisting Notice: The company received notification from Nasdaq that its common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days ending April 25, 2018.
- Grace Period: Nasdaq granted a 180-calendar-day grace period, extending through October 23, 2018, to regain compliance.
- Compliance Requirement: To maintain listing, the company must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days by the October 23, 2018 deadline.
- Market Transfer: The company previously transferred its listing from The Nasdaq Global Market to The Nasdaq Capital Market in February 2018 due to failure to meet the $35 million market value requirement.
Outlook, Risks, and Management Commentary
The notice has no immediate effect on the listing or trading of the company's common stock. However, the primary risk is the potential delisting if the company fails to meet the $1.00 bid price requirement within the specified grace period. The company is classified as an emerging growth company.
Investor Verification Checklist
- Verify the current trading price of Oncobiologics, Inc. common stock relative to the $1.00 threshold.
- Monitor the company's progress toward achieving 10 consecutive days of compliance before the October 23, 2018 deadline.
- Review the February 14, 2018 Form 8-K for details on the prior transfer from the Nasdaq Global Market.
- Confirm the company's status as an emerging growth company and any associated accounting election impacts.